Open in PodwiseOpen

Podcast cover

BioSpace · Business

BioSpace

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Episodes

Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn

Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma

Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing

Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC

Bonus: Q3 2025 Job Market Update

Shutdown Pauses New Drug Reviews, CDC Issues New COVID Guidance, CGT Meets on Mesa

Hit Me With Your Best Shot: Understanding Autoinjectors and Combination Drug Delivery Systems

M&A Picks Up, Walmsley Moves On, Pfizer’s MFN Deal and Hope for Huntington’s

FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More

What Do AI and Hammers Have in Common?

China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More

Unpacking the Latest MAHA Report, RFK’s Senate Appearance, FDA’s CRL Drop and More

The 'Research Safety Net' Saving Scientists from Funding Crisis

CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More

Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change

Oral Weight-Loss Race Heats Up as New Data From Lilly, Viking Reset Expectations

Why AI Won't Save the 90% of Clinical Trials That Still Fail

MAHA Report Emphasizes Vaccines, Safety Vexes Viking’s Obesity Win, Novo Gains Momentum

The Hidden Patent Crisis That Could Break Biotech: What Every CEO Needs to Know

Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues

Page 6

Follow this podcast in Podwise

Sign in to get AI summaries, transcripts and mind maps for any episode, including new ones.

Open in Podwise